• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Oncolytics Biotech President and CEO Brad Thompson steps down

Oncolytics Biotech President and CEO Brad Thompson steps down

November 4, 2016
CenterWatch Staff

Oncolytics Biotech has announced that Brad Thompson, Ph.D., has stepped down as president and chief executive officer of Oncolytics, effective immediately. The company's Chief Operating Officer Matt Coffey Ph.D., M.B.A., has been appointed interim president and chief executive officer while the company conducts a search for Dr. Thompson's replacement.

Dr. Thompson, along with Dr. Coffey, has led Oncolytics for 18 years—since it was founded. Wayne Pisano, chairman of the board of directors of Oncolytics, credited Dr. Thompson for advancing the company's lead candidate REOLYSIN in multiple cancer indications and, in particular, for the recent progress in lung, multiple myeloma and colorectal cancers.

"Dr. Thompson has been instrumental in the development of our Company and the progress we have seen in taking REOLYSIN into multiple phase II clinical trials," said Pisano. "On behalf of the board of directors, i would like to thank Brad for his dedication and leadership."

The Oncolytics board of directors is confident that Dr. Coffey will provide strong leadership and continue the development of REOLYSIN during the interim period until a new chief executive is announced. The board will be engaging an executive recruitment firm to assist it in this search process.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. 

Upcoming Events

  • 06Jun

    Gene & Cell Therapy Regulation: Comparability and Other New Developments

  • 07Jun

    Developing World-Class SOPs: Optimizing Quality and Compliance

  • 08Jun

    Implementing ICH E8 R1 Recommendations Increases Site and Participant Relationship Scoring Measures

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing